Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a South San Francisco-based biopharmaceutical company focused on discovering, developing, and providing novel therapies that enhance the lives of people with immune and hematological disorders, cancers, and rare diseases. Rigel’s first FDA approved product TAVALISSE™ (fostamatinib disodium hexahydrate) was approved in April 2018. Please visit www.TAVALISSE.com to learn more.